<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382198</url>
  </required_header>
  <id_info>
    <org_study_id>OttawaHRI REB 2015-0043</org_study_id>
    <nct_id>NCT02382198</nct_id>
  </id_info>
  <brief_title>Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease</brief_title>
  <acronym>GLYCOPAR</acronym>
  <official_title>A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sialorrhea is a frequently occurring problem with detrimental effect on quality of life in
      25% of PD patients. Currently, there is no intervention approved for sialorrhea in Parkinsons
      and evidence is only available for a 30-day effect or less. We hypothesize that
      glycopyrrolate will have a lasting effect in the reduction of sialorrhea in PD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assses if Glycopyrrolate has a long lasting effect on sialorrhea for patients with
      Parkinsons.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sialorrhea related-disability at end of treatment (day 90) measured by the patient/caregiver-rated ROMP-saliva.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean score in sialorrhea severity at end of treatment (day 90) measured by the sialorrhea scoring scale</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a reduction of severity of sialorrhea in at least one point from baseline to end of treatment (day 90), measured by the MDS-UPDRS, item 2.2.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Sialorrhea</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Active Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive the study drug glycopyrrolate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Drug to reduce drooling in patients with Parkinson's Decease.</description>
    <arm_group_label>Active Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PD as defined by United Kingdom PD Society Brain Bank criteria

          -  Moderate-to-severe sialorrhea defined by a score in the item 2.2 of the MDS-UPDRS
             greater than 2

        Exclusion Criteria:

          1. Other idiopathic parkinsonian syndromes, e.g., Progressive Supranuclear Palsy,
             Cortico-basal syndrome, or Multiple System Atrophy

          2. Secondary parkinsonian syndromes (drug-induced, traumatic, encephalitic or vascular)

          3. Change in antiparkinsonian medication one month prior to enrolment

          4. Prior use of glycopyrrolate with or without known hypersensitivity will be considered
             an exclusion criterion, as it increases the risk of unblinding due to prior knowledge
             of potential side effects or therapeutic benefit

          5. Change in the dose one month prior to enrolment of other anticholinergic agents or
             other drugs potentially affecting saliva production, such as tricyclic
             antidepressants, MAO-A inhibitors, neuroleptics (including clozapine and quetiapine
             more frequently used in PD) or hypnotics. These medication will remain in a constant
             dose throughout the trial;

          6. Concomitant use of solid oral dosage forms of potassium chloride;

          7. Pregnancy, breastfeeding, and premenopausal females or males not using adequate
             contraception; medically acceptable birth control methods for this study include: (1)
             Abstinence (no sexual intercourse); (2) Intrauterine device (IUD); (3) Diaphragm with
             spermicide; (4) Condom with spermicide; and (5) Oral contraceptives (birth control
             pills) + condom/diaphragm with spermicide.

          8. Moderate-to-severe constipation in spite of optimal treatment (MDS-UPDRS, item
             1.11&gt;2);

          9. Conditions that preclude anticholinergic therapy, e.g., documented history or symptoms
             suggestive of inflammatory bowel disease, glaucoma, myasthenia gravis, prostatic
             hypertrophy or obstructive urinary symptoms;

         10. Conditions that can be exacerbated by anticholinergic effects of glycopyrrolate, e.g.,
             documented history or symptoms suggestive of congestive heart failure, coronary heart
             disease, gastro-esophageal reflux disease or hyperthyroidism;

         11. Uncontrolled arterial hypertension (TAS&gt;140 mmHg or TAD&gt;90 mmHg, using an electronic
             sphygmomanometer and standardized procedure16);

         12. Tachyarrhythmia (interval RR &lt;0.6 sec.);

         13. TSH&lt;0.4 mIU/L;

         14. Liver dysfunction (AST, ALT, ALP &gt;2xUpper Normal Limit);

         15. Renal dysfunction (creatinine clearance &lt;50 mL/min), as glycopyrrolate has predominant
             renal clearance;

         16. Inability or unwillingness of subject or legal guardian/representative to give written
             informed consent;

         17. Clinical significant lactose intolerance or known hypersensitivity to any of the study
             medication excipients

         18. Participation in another investigational study at the time of recruitment or during
             the prior month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiago Mestre, MSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawna Reddie</last_name>
    <phone>613-798-5555</phone>
    <phone_ext>19369</phone_ext>
    <email>sreddie@ohri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiago Mestre, MSc, MD</last_name>
    <phone>613-798-5555</phone>
    <phone_ext>18986</phone_ext>
    <email>tmestre@toh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ottawa Hospital - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Reddie</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>19369</phone_ext>
      <email>sreddie@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tiago Mestre, MSc, MD</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>18986</phone_ext>
      <email>tmestre@toh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Tiago Mestre, MSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Tian</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>3415</phone_ext>
      <email>Alison.Tian@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Susan Fox, MBChB, MRCP, PhD</last_name>
      <phone>416-699-9837</phone>
      <email>Sfox@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Fox, MBChB, MRCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>droooling, sialorrhea, parkinson's disease, parkinsons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sialorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

